At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the updated response and survival data of a phase 1a study of the anti-PDL1 antibody, MPDL3280A, for the treatment of patients with metastatic urothelial bladder cancer.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews